LivaNova PLC (LIVN)

NASDAQ: LIVN · IEX Real-Time Price · USD
46.85
+1.25 (2.74%)
Jun 2, 2023, 4:00 PM EDT - Market closed
2.74%
Market Cap 2.52B
Revenue (ttm) 1.05B
Net Income (ttm) -81.87M
Shares Out 53.77M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE 24.45
Dividend n/a
Ex-Dividend Date n/a
Volume 297,689
Open 46.08
Previous Close 45.60
Day's Range 45.84 - 46.92
52-Week Range 40.26 - 70.57
Beta 0.86
Analysts Buy
Price Target 56.25 (+20.06%)
Earnings Date May 3, 2023

About LIVN

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device tha... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 10, 1993
Employees 2,900
Stock Exchange NASDAQ
Ticker Symbol LIVN
Full Company Profile

Financial Performance

In 2022, LivaNova's revenue was $1.02 billion, a decrease of -1.31% compared to the previous year's $1.04 billion. Losses were -$86.25 million, -36.50% less than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $56.25, which is an increase of 20.06% from the latest price.

Price Target
$56.25
(20.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Primecap Management Pumps Up LivaNova Position

Media-shy investment firm PRIMECAP Management (Trades, Portfolio) revealed earlier this week it upped its stake in LivaNova PLC ( LIVN , Financial), which had an impact of 0.04% on the equity portfoli...

3 weeks ago - GuruFocus

LivaNova Reports First-Quarter 2023 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.

1 month ago - Business Wire

LivaNova Board of Directors Announce Leadership Changes

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effectiv...

1 month ago - Business Wire
}

LivaNova to Announce First-Quarter 2023 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, Ma...

2 months ago - Business Wire

LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance f...

3 months ago - Business Wire

LivaNova to Present at the Barclays Global Healthcare Conference

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside c...

3 months ago - Business Wire

LivaNova Reports Fourth-Quarter and Full-Year 2022 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.

3 months ago - Business Wire

LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced the start of a limited commercial release in Europe for the Essenz™ Perfusion System.

4 months ago - Business Wire
}

LivaNova Launches SenTiva DUO

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO™, an implantable pulse generator (IPG) with a dual-pin he...

4 months ago - Business Wire

LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results...

4 months ago - Business Wire

LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administr...

6 months ago - Business Wire

LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual...

6 months ago - Business Wire

LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation...

7 months ago - Business Wire
}

LivaNova to Present at the Stifel, Wolfe and Piper Sandler Healthcare Conferences

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced its CEO Damien McDonald will present in fireside chats at three healthcare conferences in New York this month.

7 months ago - Business Wire

LivaNova Reports Third-Quarter 2022 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 3...

7 months ago - Business Wire

LivaNova to Announce Third-Quarter 2022 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its third-quarter 2022 results on Wednesday, Nov. 2, 2022, at 12 p.m. London time (8 a.m. EDT...

9 months ago - Business Wire

LivaNova Board Appoints Brooke Story as a New Director

LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022.

Other symbols: BDX
9 months ago - Business Wire

LivaNova Reports Second-Quarter 2022 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022.

10 months ago - Business Wire

LivaNova to Announce Second-Quarter 2022 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1 p.m. London time (8 a.m. EDT).

1 year ago - Business Wire

LivaNova Elects Peter Wilver to Board of Directors

LONDON--(BUSINESS WIRE)--LivaNova PLC today announced Peter Wilver has been elected to the Board of Directors, effective immediately.

1 year ago - Business Wire

LivaNova to Present at the Goldman Sachs Global Healthcare Conference

LONDON--(BUSINESS WIRE)--LivaNova PLC announced CEO Damien McDonald will present in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15.

1 year ago - Business Wire

LivaNova Reports First-Quarter 2022 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.

1 year ago - Business Wire

LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures

LONDON--(BUSINESS WIRE)--LivaNova PLC today announced receipt of regulatory approvals and the start of a targeted commercial launch for the Essenz Patient Monitor.

1 year ago - Business Wire

LivaNova to Announce First-Quarter 2022 Results

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m. London time (8 a.m. EDT).

1 year ago - Business Wire

LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study

LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study.

1 year ago - Business Wire